- Home
- CMMB vs AEHL Comparison
CMMB vs AEHL Comparison
Compare CMMB & AEHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- AEHL
- Stock Information
- Founded
- CMMB 2004
- AEHL 1993
- Country
- CMMB Israel
- AEHL China
- Employees
- CMMB N/A
- AEHL N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- AEHL Building Materials
- Sector
- CMMB Health Care
- AEHL Industrials
- Exchange
- CMMB Nasdaq
- AEHL Nasdaq
- Market Cap
- CMMB 22.0M
- AEHL 17.9M
- IPO Year
- CMMB N/A
- AEHL 2007
- Fundamental
- Price
- CMMB $2.83
- AEHL $2.88
- Analyst Decision
- CMMB Strong Buy
- AEHL
- Analyst Count
- CMMB 2
- AEHL 0
- Target Price
- CMMB $26.50
- AEHL N/A
- AVG Volume (30 Days)
- CMMB 141.5K
- AEHL 1.8M
- Earning Date
- CMMB 11-13-2025
- AEHL 09-25-2025
- Dividend Yield
- CMMB N/A
- AEHL N/A
- EPS Growth
- CMMB N/A
- AEHL N/A
- EPS
- CMMB N/A
- AEHL N/A
- Revenue
- CMMB N/A
- AEHL $98,773,000.00
- Revenue This Year
- CMMB N/A
- AEHL N/A
- Revenue Next Year
- CMMB N/A
- AEHL N/A
- P/E Ratio
- CMMB N/A
- AEHL N/A
- Revenue Growth
- CMMB N/A
- AEHL 36.99
- 52 Week Low
- CMMB $2.71
- AEHL $1.79
- 52 Week High
- CMMB $9.84
- AEHL $44.80
- Technical
- Relative Strength Index (RSI)
- CMMB 21.60
- AEHL 42.22
- Support Level
- CMMB $2.96
- AEHL $3.49
- Resistance Level
- CMMB $3.09
- AEHL $8.42
- Average True Range (ATR)
- CMMB 0.21
- AEHL 0.71
- MACD
- CMMB 0.00
- AEHL -0.03
- Stochastic Oscillator
- CMMB 11.26
- AEHL 4.65
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About AEHL Antelope Enterprise Holdings Limited
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.